Schedule 13D Amendment No. 17

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 17)

 

 

 

M.D.C. HOLDINGS, INC.

(Name of Issuer)

 

 

 

Common Stock, $0.01 Per Share

(Title of Class of Securities)

 

552676108

(CUSIP Number)

 

David D. Mandarich, 4350 S. Monaco St., Suite 500, Denver, CO 80237

(303) 773-1100

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

February 3, 2012

(Date of Event which Requires Filing of this Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1 (e), 13d-1(f) or 13d-1(g), check the following box  ¨.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

Page 1 of 4


SCHEDULE 13D

 

CUSIP No. 552676108   Page 2 of 4 Pages

 

  1   

NAME OF REPORTING PERSON

 

David D. Mandarich

  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)  ¨        (b)  ¨

 

Not Applicable

  3  

SEC USE ONLY

 

  4  

SOURCE OF FUNDS

 

OO

  5  

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2 (e)  ¨

 

Not Applicable

  6  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States of America

  7   

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH SOLE VOTING POWER

 

4,259,806

  8  

SHARED VOTING POWER

 

0

  9  

SOLE DISPOSITIVE POWER

 

4,259,806

  10    

SHARED DISPOSITIVE POWER

 

0

  11  

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,259,806

  12  

 

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES    ¨

 

Not Applicable

  13  

 

PERCENT OF CLASS REPRESENTED BY THE AMOUNT IN ROW (11)

 

8.7%

  14  

 

TYPE OF REPORTING PERSON

 

IN


CUSIP NO. 552676108    SCHEDULE 13D    Page 3 of 4 Pages

 

AMENDMENT

NO. 17

TO THE

SCHEDULE 13D

The Reporting Person, David D. Mandarich, hereby amends his Schedule 13D relating to Common Stock, par value $0.01, of M.D.C. Holdings, Inc.

 

Item 5. Interest in Securities of the Issuer

According to the Form 10-K of the Issuer dated December 31, 2011, there were 47,957,196 shares of the Issuer’s Common Stock outstanding as of December 31, 2011.

 

  (a) Amount beneficially owned as of the close of business on February 3, 2012: 4,259,806 shares of Common Stock

Percent of class: 8.7%

 

  (b) The number of shares as of the close of business on February 3, 2012 as to which Reporting Person has:

(i) Sole power to vote or direct the vote: 4,259,806 shares;

(ii) Shared power to vote or direct the vote: 0 shares;

(iii) Sole power to dispose or direct the disposition of: 4,259,806 shares

(iv) Shared power to dispose or direct the disposition of: 0 shares.

The number of shares set forth in Item 5(a) includes 3,419 shares of Common Stock held in the Reporting Person’s 401(k) Plan account (which changes on a daily basis) and 1,223,127 shares of Common Stock that the Reporting Person has the right to acquire within 60 days of February 3, 2012 by the exercise of options.

 

  (c) The following table sets forth the transactions by the Reporting Person named in response to Item 5(a) during the past sixty days.

 

 

Trade Date

  Price per Share ($)   David D. Mandarich
       

(1)    

 

(1) This is a voluntary filing to reflect changes in Reporting Person’s holdings over the prior year.


CUSIP NO. 552676108    SCHEDULE 13D    Page 4 of 4 Pages

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 3, 2012.

 

By:  

  /s/ David D. Mandarich

  David D. Mandarich